Jennifer Michaelson
Chief Scientific OfficerDr. Jennifer Michaelson, also known as Jen, Ph.D. serves as Chief Scientific Officer at Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) since June 2023 and was its Chief Development Officer since February 2022 until June 2023 and served as Chief Development Officer of Biologics since January 2020 until February 2022 and was its Vice President of Preclinical Research and Development at Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) since January 2018 until December 2019. She was also a Member of the Leadership Team at Jounce. Previously, during her tenure at Biogen, she served as project leader for several monoclonal antibody and bispecific antibody programs in both the Oncology and Immunology therapeutic areas. She has also worked as a consultant at Third Rock Ventures for multiple stealth companies. She served as the Head of Biologics at Celsius Therapeutics, Inc. since July 2017 until December 2017. She served in increasing roles of responsibility at Jounce Therapeutics, Inc. since September 2012 until July 2017, most recently as Senior Director and Executive Program Leader and previously as Director of Tumor Immunology and as a consultant. She received her B.A. in Biology from Princeton University and Ph.D from the Department of Cell Biology at Albert Einstein College of Medicine and completed a post-doctoral fellowship in Philip Leder’s laboratory in the Department of Genetics at Harvard Medical School.
Positions
- Company NameCullinan Therapeutics, Inc.Stock CodeCGEMPositionChief Scientific OfficerColleagues
- NANadim AhmedPresident, CEO & Director
- AAAnthony A. RosenbergIndependent Chairman of the Board
- MKMary Kay FentonChief Financial Officer
- JJJeffrey JonesChief Medical Officer
- PAPatrick A. BaeuerleCo-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
- SWStephen W. WebsterIndependent Director
- DDDavid D. MeekIndependent Director
